87.40
+0.9(+1.04%)
Currency In USD
| Previous Close | 86.5 |
| Open | 85.87 |
| Day High | 89.28 |
| Day Low | 85.6 |
| 52-Week High | 103 |
| 52-Week Low | 19.45 |
| Volume | 1.03M |
| Average Volume | 983,401 |
| Market Cap | 6.9B |
| PE | -24.28 |
| EPS | -3.6 |
| Moving Average 50 Days | 77.51 |
| Moving Average 200 Days | 55.27 |
| Change | 0.9 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $2,627.78 as of February 21, 2026 at a share price of $87.4. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 5 years ago, it would be worth $1,674.01 as of February 21, 2026 at a share price of $87.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewswire Inc.
Jan 29, 2026 12:00 PM GMT
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) --
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
GlobeNewswire Inc.
Jan 13, 2026 12:00 PM GMT
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 A